{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52.1","upperLimit":"79.2","value":"66.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"CR rate is the percent of participants who show CR (disappearance of all evidence of disease) according to the 2007 IWG criteria at the planned end of study therapy radiographic tumor assessment.\n\nConfidence interval based on the Klopper and Pearson method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Four doses of nivolumab flat dose 240 mg IV were administered every 2 weeks (monotherapy phase), followed by 12 doses of the combination of AVD (adriamycin/ doxorubicin 25 mg/m2, vinblastine 6 mg/m2, dacarbazine 375 mg/m2) chemotherapy and nivolumab flat dose 240 mg IV for 6 cycles (combination phase).","id":"OG000","title":"Cohort D: Newly Diagnosed, Previously Untreated Advanced Stage cHL (Stage IIB, III and IV)"}],"paramType":"NUMBER","populationDescription":"All Cohort D participants treated in the monotherapy and combination therapy phases.","reportingStatus":"POSTED","timeFrame":"From first dose to the date of initial objectively documented progression or the date of subsequent therapy, or death whichever occurred first (up to approximately 100 months)","title":"Complete Response (CR) Rate at Planned End of Therapy Based on IRRC Assessments in Cohort D","type":"SECONDARY","unitOfMeasure":"Percent of Participants"}